Back to Search
Start Over
Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.
- Source :
-
Hepatology research : the official journal of the Japan Society of Hepatology [Hepatol Res] 2024 Mar; Vol. 54 (3), pp. 315-319. Date of Electronic Publication: 2023 Oct 24. - Publication Year :
- 2024
-
Abstract
- A 72-year-old man with metastatic hepatocellular carcinoma previously received first-line systemic therapy with atezolizumab plus bevacizumab. His disease was judged to be progressing 5 months after treatment initiation. Comprehensive genomic profiling revealed cytoplasmic mesenchymal-epithelial transition factor amplification. On the basis of an expert panel's recommendation, he received cabozantinib as second-line therapy. The tumors shrank markedly and continued to shrink 6 months after treatment. Comprehensive genomic profiling could provide useful information for selecting effective second-line treatments for patients with hepatocellular carcinoma after first-line immunotherapy.<br /> (© 2023 Japan Society of Hepatology.)
Details
- Language :
- English
- ISSN :
- 1386-6346
- Volume :
- 54
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Hepatology research : the official journal of the Japan Society of Hepatology
- Publication Type :
- Report
- Accession number :
- 37817425
- Full Text :
- https://doi.org/10.1111/hepr.13975